Today: 10 June 2026
Browse Category

NYSE:NVO 3 July 2025 - 15 October 2025

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk will pay up to $2.1 billion to license Omeros’s experimental MASP-3 inhibitor zaltenibart for rare blood and kidney disorders. Omeros receives $340 million upfront, with additional milestone and royalty payments possible. Omeros shares jumped about 65% on the news, while Novo’s stock fell 1.5%. The deal is expected to close by Q4 2025.
15 October 2025
···
Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Akero shares jumped nearly 19% to $55 on October 9, 2025 after Novo Nordisk announced a $5.2 billion buyout at $54 per share plus a $6 contingent payment. Novo will pay $4.7 billion upfront and another $500 million if Akero’s lead drug, efruxifermin, wins FDA approval by 2031. The deal has board approval and is expected to close by late 2025, pending regulatory and shareholder clearance.
9 October 2025
···
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk will acquire Akero Therapeutics for up to $5.2 billion, paying $54 per share in cash plus a potential $6 per share if Akero’s lead drug wins U.S. approval by 2031. Akero’s efruxifermin, in Phase 3 trials for fatty liver disease, has shown reversal of liver fibrosis in mid-stage studies. Akero shares jumped 19% on the news, while Novo shares were little changed. The deal is expected to close by year-end.
9 October 2025
··
Tariff Shocks & Rate Jitters Ignite Wild 48 Hours in European Markets

Tariff Shocks & Rate Jitters Ignite Wild 48 Hours in European Markets

European stocks hit three-week lows Thursday, then rebounded Friday as the STOXX 600 fell 0.7% before rising 0.3%. U.S. President Trump’s new tariffs on drugs and trucks triggered a 2% drop in major pharma and truck stocks. The Bank of England warned on persistent UK inflation, while the ECB and Swiss National Bank held rates steady. Germany’s consumer confidence improved; Spain’s GDP beat forecasts.
26 September 2025
········
Weekend Science Bonanza: Breakthroughs From Space to Superbugs

Weekend Science Bonanza: Breakthroughs From Space to Superbugs

NASA confirmed its 6,000th exoplanet discovery, while astronomers observed a black hole speeding away at over 50 km/s after a merger. A weight-loss pill version of Ozempic led to 16% body weight loss in trials, and a quick EEG test detected early Alzheimer’s. Engineers nearly doubled refrigeration efficiency with nano-thin films. AI designed viruses that killed drug-resistant E. coli in lab tests.
21 September 2025
···
Ozempic for Alzheimer’s? How GLP-1 Weight-Loss Drugs Could Fight Neurodegenerative Diseases

Ozempic for Alzheimer’s? How GLP-1 Weight-Loss Drugs Could Fight Neurodegenerative Diseases

A 2024 trial found liraglutide reduced brain shrinkage by about 50% and slowed cognitive decline in mild Alzheimer’s, but missed its main goal. Larger semaglutide trials are underway, with results expected in late 2025. A major exenatide trial in Parkinson’s showed no benefit, while ALS studies remain inconclusive. Pharmaceutical companies are expanding research into GLP-1 drugs for neurodegenerative diseases.
10 September 2025
·
Glowing Planets, Monster Blooms & a ‘Next Ozempic’ – Science Highlights (Sept 1–2, 2025)

Glowing Planets, Monster Blooms & a ‘Next Ozempic’ – Science Highlights (Sept 1–2, 2025)

Chemists unveiled a “4-in-1” obesity drug targeting four hormones for bariatric surgery-level weight loss, aiming to avoid Ozempic’s side effects. German neuroscientists traced early Alzheimer’s smell loss to immune cells destroying neural links. A study warns the Atlantic’s ocean circulation could collapse after 2100 under high emissions. The Great Atlantic Sargassum Belt hit a record 37.5 million tons, fouling beaches from Africa to the Gulf of Mexico.
2 September 2025
·
Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

The U.S. administration fired CDC Director Dr. Susan Monarez after she resisted Health Secretary Robert F. Kennedy Jr.’s directives; four senior CDC officials resigned in protest, citing risks to young Americans and pregnant women. U.S. regulators approved updated COVID-19 vaccines for fall, but limited routine access to adults 65+ and high-risk groups, excluding healthy under-65s.
28 August 2025
····
Breakthrough Cures, Billion-Dollar Bets & Health Shockers – Global Biotech & Health News Roundup (Aug 23–24, 2025)

Breakthrough Cures, Billion-Dollar Bets & Health Shockers – Global Biotech & Health News Roundup (Aug 23–24, 2025)

The FDA cleared Rocket Pharma to resume its gene therapy trial for Danon disease after a patient death halted the study in May; the trial will restart with a lower dose and without the immune-suppressing drug linked to the fatal complication. Rocket shares jumped over 30% after the decision. Early data showed Dynavax’s shingles vaccine matched GSK’s Shingrix in immune response but caused fewer side effects, sending Dynavax shares up 7%.
24 August 2025
···
Tariff Tsunami, Tech Tumble & Peace Talk Buzz – Global Business Roundup (Aug 19–20, 2025)

Tariff Tsunami, Tech Tumble & Peace Talk Buzz – Global Business Roundup (Aug 19–20, 2025)

Nvidia shares fell sharply on August 19, 2025, as a tech selloff pulled the Nasdaq down 1.5%. President Trump met Ukraine’s president and pledged U.S. support for Ukraine’s security in any peace deal. The U.S. Commerce Department expanded 232 tariffs to 407 new categories, affecting over $200 billion in imports. New Zealand’s central bank cut rates to 3.00%, sending the kiwi dollar to $0.584.
20 August 2025
········
Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

The FDA approved Tonix’s Tonmya as the first new fibromyalgia drug in over 15 years. Novo Nordisk’s Wegovy received accelerated FDA approval for MASH, becoming the first GLP-1 therapy cleared for the liver disease. Pfizer’s sickle cell drug inclacumab failed a Phase 3 trial, marking another setback after its $5.4 billion Global Blood Therapeutics acquisition. Eli Lilly announced a $1.3 billion AI drug partnership with Superluminal.
18 August 2025
·····
Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Wegovy became the first GLP-1 therapy approved by the FDA for MASH, affecting about 5% of U.S. adults. Tonix’s Tonmya was cleared for fibromyalgia, the first new therapy in 15 years. Pfizer’s inclacumab failed a key sickle cell trial, and Oxbryta was withdrawn. BioNTech agreed to acquire CureVac in a $1.25 billion all-stock deal.
16 August 2025
··········
Global Business Pulse: Markets Juggle Tariffs, Rate Cuts & Mega-Deals (Aug 7–8, 2025)

Global Business Pulse: Markets Juggle Tariffs, Rate Cuts & Mega-Deals (Aug 7–8, 2025)

The United States imposed 100% tariffs on imported chips and electronics Aug. 7, sending Apple shares up 3%. Dow Jones fell 0.5%, S&P 500 slipped 0.1%, and Nasdaq hit a record, while Eli Lilly dropped 14% on weak drug data. The Bank of England cut rates for a fourth time, lifting the pound 0.7%. Paramount Global and Skydance completed an $8.4 billion merger.
8 August 2025
········
Digital Health & Telemedicine Industry Update (June–July 2025)

Digital Health & Telemedicine Industry Update (June–July 2025)

DispatchHealth and Medically Home merged in June 2025, creating one of the largest high-acuity hospital-at-home providers under the DispatchHealth name. Novo Nordisk ended its Wegovy deal with Hims & Hers Health in late June over compounded drug concerns, causing Hims & Hers shares to drop 30%. Teladoc Health shifted strategy after acquiring Catapult Health and UpLift earlier in the year.
3 July 2025
····
1 … 5 6 7

Stock Market Today

  • Tencent Shares Rise 3.22% After $4.66 Billion Bond Sale Fuels AI Investment
    June 10, 2026, 5:05 AM EDT. Tencent Holdings Ltd shares rose 3.22% to HK$467.80 in Hong Kong following the pricing of a US$4.66 billion dual-currency bond deal, comprising US$2.45 billion in dollar notes and CNY15 billion in offshore yuan notes. The bond sale attracted over US$17 billion in orders, allowing Tencent to cut pricing across four tranches. The company plans to use proceeds for general corporate purposes, including refinancing. Investors reacted positively despite Tencent's increased spending on artificial intelligence (AI), with first-quarter capital expenditures at RMB31.94 billion and free cash flow of RMB56.7 billion. CFO John Lo highlighted Tencent's strong balance sheet as the firm balances debt issuance with AI financing needs.

Latest articles

Roche Shares Edge Up After $2.3 Billion Nurix Cancer Pact

Roche Shares Edge Up After $2.3 Billion Nurix Cancer Pact

10 June 2026
Roche’s participation certificates climbed 1.07% to CHF 322.20 after announcing a $2.3 billion deal with Nurix Therapeutics for late-stage blood-cancer drug bexobrutideg, planned to enter Phase 3 trials this summer in CLL, as investors weigh the asset’s potential to offset losses from expiring patents and drive mid-single-digit sales growth in 2026.
YY Group Shares Jump Premarket on Humanoid Robot Move

YY Group Shares Jump Premarket on Humanoid Robot Move

10 June 2026
YYGH jumped to $0.19 in early pre-market after announcing deployment of Unitree G1 humanoid robots for facility management, aiming to turn operational know-how into higher-margin data assets, but the stock remains volatile near record lows after a recent reverse split and has not confirmed robot-driven revenue or margin gains.
Tencent Shares Gain After $4.66B Bond Sale Seen Fueling AI Bets

Tencent Shares Gain After $4.66B Bond Sale Seen Fueling AI Bets

10 June 2026
Tencent shares jumped 3.22% to HK$467.80 after the company priced a larger-than-expected US$4.66 billion dual-currency bond deal, drawing over US$17 billion in orders and allowing tighter pricing, as investors weighed Tencent’s ability to fund rising AI investments while maintaining strong cash flow and ongoing share buybacks.
PAVS Stock Jumps Again, $195M Share Sale Filing in Focus

PAVS Stock Jumps Again, $195M Share Sale Filing in Focus

10 June 2026
Paranovus Entertainment Technology shares jumped 19.6% premarket after filing plans for an at-the-market share sale of up to $194.99 million—an unusually large amount compared to its $1.07 million market value—raising dilution risks as the company can sell shares at prevailing prices with no minimums, while recent trading has been highly volatile and underlying operations remain limited.
Marvell Is Now in the S&P 500. The Focus Turns to Its Next Move

Marvell Is Now in the S&P 500. The Focus Turns to Its Next Move

10 June 2026
Marvell plunged 7.6% to $266.88 after Monday’s S&P 500-driven surge, as semiconductor stocks sold off despite the chipmaker’s looming June 22 index inclusion and strong AI demand; shares had soared 59% since May 27 on bullish custom-chip forecasts, but high valuation and sector volatility now threaten further gains.
Go toTop